Research

Addiction Recovery Statistics: 2026 Report

By Emily Chen, LCSW, Licensed Clinical Social Worker · 8 min read · Published 2026-01-14 · Updated 2026-02-20
Medically reviewed by Dr. Amanda Foster, PhD, Clinical Research Director

Addiction and Recovery in America: The Numbers That Matter

46.8 million Americans aged 12 and older met criteria for a substance use disorder in 2023, according to SAMHSA's National Survey on Drug Use and Health. That is 16.7% of the population — roughly 1 in 6 people. Of those, only 24.1% received any form of treatment. The treatment gap — the distance between need and access — remains the defining challenge of American addiction care.

But there is another statistic that rarely makes headlines: 72.2 million Americans report being in recovery from a substance use or mental health condition (SAMHSA, 2024). Recovery is not rare. It is common, achievable, and happening every day across the country. The problem is not that treatment does not work — it is that too few people receive it.

This data compendium brings together the most current statistics from SAMHSA, NIDA, the CDC, and peer-reviewed research to provide a clear, evidence-based picture of where addiction and recovery stand today.

Prevalence: Who Is Affected?

  • 46.8 million Americans had a substance use disorder in 2023 (SAMHSA NSDUH).
  • 29.5 million had alcohol use disorder — the most common single SUD.
  • 27.2 million had a drug use disorder (some overlap with alcohol).
  • 9.2 million adults had co-occurring mental health and substance use disorders (dual diagnosis).
  • 2.4 million had opioid use disorder specifically — down slightly from 2.7 million in 2021, likely reflecting both treatment gains and mortality.
  • 1.6 million adolescents aged 12-17 had a substance use disorder (see our teen substance abuse guide).

Demographics

SUD affects every demographic, but not equally. Men are 1.5x more likely than women to have SUD. Native Americans and Alaska Natives have the highest rates of any racial/ethnic group (22.7%). Adults aged 18-25 have the highest age-specific prevalence (27.8%). Rural areas show higher opioid mortality rates but lower treatment access.

LGBTQ+ adults have approximately 2x the rate of SUD compared to the general population, driven by minority stress, discrimination, and higher rates of trauma. Our LGBTQ+ treatment guide covers culturally affirming care options.

Treatment Access: The Gap Remains Wide

  • 24.1% of people with SUD received treatment in 2023 — up from 18.1% in 2019, but still leaving 35.5 million people untreated.
  • Top barriers to treatment (SAMHSA 2023): not ready to stop using (40.7%), cost/insurance concerns (30.2%), stigma/what others would think (22.8%), not knowing where to go (18.6%), couldn't find program accepting their insurance (15.3%).
  • Wait times: Average wait for residential treatment is 14 days in urban areas, 30+ days in rural areas.
  • Treatment workforce shortage: The U.S. has approximately 38,000 addiction counselors — serving 47 million people with SUD. That is a ratio of 1:1,237.
  • MAT access: Only 22% of people with opioid use disorder receive medication-assisted treatment, despite it being the gold standard. Expansion of telehealth buprenorphine prescribing has improved access since 2023.

If you or a loved one needs treatment, do not wait. Call SAMHSA's helpline at 1-800-662-4357 or our team at (855) 537-4180 to find available programs immediately.

Overdose Crisis: Current Data

  • 107,543 overdose deaths in the U.S. in 2023 (CDC WONDER provisional data). Down slightly from 109,680 in 2022 — the first year-over-year decrease since 2018.
  • Opioids accounted for 75% of all overdose deaths. Synthetic opioids (primarily fentanyl) drove 90% of opioid deaths.
  • Stimulants — methamphetamine and cocaine overdose deaths rose 12% in 2023, increasingly involving fentanyl contamination. See our meth recovery guide.
  • Xylazine ("tranq") — detected in 35% of fentanyl samples tested by DEA in 2024, causing severe tissue necrosis and complicating overdose reversal (naloxone is less effective).
  • Naloxone access: Over 3.2 million naloxone kits were distributed in 2023 through harm reduction programs, contributing to the decline in overdose deaths.

The overdose crisis is evolving, not ending. Polysubstance use (fentanyl + stimulants + xylazine) is now the dominant pattern, requiring more sophisticated treatment approaches.

Recovery Outcomes: Treatment Works

  • 72.2 million Americans identify as being in recovery (SAMHSA, 2024) — proof that long-term recovery is achievable and common.
  • Treatment completion rates: 52% for residential programs, 41% for outpatient, 34% for detox-only (SAMHSA TEDS 2023). Programs longer than 90 days show 25-40% better retention.
  • Post-treatment sobriety: Among those who complete treatment and engage in aftercare, approximately 40-60% maintain sobriety at one year (NIDA). This rate improves significantly with MAT and ongoing support.
  • Relapse rates: 40-60% — comparable to type 2 diabetes (40-70%), hypertension (50-70%), and asthma (50-70%). Relapse indicates a need for treatment adjustment, not treatment failure. See our relapse perspective guide.
  • Economic return: Every $1 invested in addiction treatment yields $4-$7 in reduced drug-related crime, criminal justice costs, and theft. Including healthcare savings, the return reaches $12:$1 (NIDA).

For information on what to expect during treatment, see our guides on inpatient rehab, holistic approaches, and aftercare planning.

Emerging Trends in 2025-2026

  • Telehealth expansion: Post-pandemic telehealth policies for buprenorphine prescribing are now permanent. Telehealth SUD visits increased 500% between 2019 and 2024.
  • Harm reduction integration: More states fund naloxone distribution, syringe services, and drug-checking programs as part of the treatment continuum rather than alternatives to it.
  • Psychedelic-assisted therapy research: Phase 3 clinical trials for psilocybin (alcohol use disorder) and MDMA (PTSD with comorbid SUD) continue, with FDA decisions anticipated in 2026-2027.
  • AI-powered early intervention: Predictive analytics in emergency departments and primary care settings identify high-risk patients for proactive outreach.
  • Contingency management expansion: Financial incentives for negative drug screens, long underfunded, are being adopted by more Medicaid programs following Montana and California pilots showing 50% reduction in stimulant use.

Frequently Asked Questions About Recovery Statistics

What percentage of people recover from addiction?
SAMHSA reports that 72.2 million Americans identify as being in recovery. Among those who complete evidence-based treatment and engage in ongoing aftercare, 40-60% maintain sobriety at one year. With sustained MAT and support, 5-year recovery rates exceed 60%. Recovery is common and achievable.
Is relapse common?
Yes. Relapse rates for substance use disorders (40-60%) are comparable to other chronic medical conditions like diabetes and hypertension. Relapse is not failure — it is a clinical event that indicates the treatment plan needs adjustment. Many people require multiple treatment episodes before achieving sustained recovery. Our relapse guide explores this in depth.
How much does addiction cost the United States?
Substance misuse costs the U.S. approximately $600 billion annually: $249 billion for alcohol misuse, $193 billion for illicit drugs, and $168 billion for tobacco (NIDA, adjusted for 2024). This includes healthcare, lost productivity, criminal justice costs, and social welfare. Every dollar spent on treatment saves $4-$12.
Are overdose deaths increasing or decreasing?
2023 saw the first year-over-year decrease in overdose deaths since 2018 (107,543, down from 109,680 in 2022). This decline is attributed to expanded naloxone distribution, MAT access, and harm reduction programs. However, the absolute number remains catastrophically high, and new challenges (xylazine contamination, polysubstance use) continue to evolve.

Last updated: 2026-02-20